Safety of long-acting β-agonists: Urgent need to clear the air remains

European Respiratory Journal

Volumn 33, Issue 1, 2009, Pages 3-5

  Beasley, R ^a   Martinez, F D ^b   Hackshaw, A ^c,d   Rabe, K F ^f   Sterk, P J ^g   Djukanovic, R ^e  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b UNIVERSITY OF ARIZONA   (United States)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL;

ASTHMA; CAUSE OF DEATH; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; LUNG FUNCTION; MONOTHERAPY; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; UNITED KINGDOM;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ASTHMA; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS;

EID: 58849160015     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00163408     Document Type: Editorial

References (26)

1. 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J 1991; 4: 218-226.
2. Nelson HS. β-adrenergic bronchodilators. N Engl J Med 1995; 333: 499-506.
3. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med 2005; 99: 1263-1267.
4. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113: 245-251.
5. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.
6. Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97: 29-37.
7. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198-1203.
8. 2-agonist. Am J Respir Crit Care Med 1996; 154: 1603-1607.
9. Arvidsson P, Larsson S, Löfdahl C-G, Melander B, Svedmyr N, Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-1173.
10. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993; 306: 1034-1037.
11. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
12. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330: 117-123.
13. Maringe C, Rickard K, DiSantostefano R, Davis K, Kiri V. Concomitant use of long-acting β-agonists with inhaled corticosteroids among asthma patients in the UK primary care. Eur Respir J 2007; 30: Suppl. 51, P3698.
14. Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Pulmonary-Allergy Drugs Advisory Committee.www.fda.gov/ ohrms/dockets/ac/05/minutes/2005-4148M1-Final.pdf Last accessed: July 2008. Last updated: June 13, 2005.
15. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33: 21-32.
16. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2006. www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60 Date last accessed: November 5, 2008.
17. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-178.
18. British Thoracic Society Scottish Intercollegiate Guidelines Network, British Guideline on the Management of Asthma. Thorax 2008; 63: Suppl. 4, iv1-iv121.
19. Wijesinghe M, Perrin K, Harwood M, Weatherall M, Beasley R. The risk of asthma mortality with long-acting inhaled beta-agonists. Postgrad Med J 2008; 84: 467-472.
20. Di Santostefano RL, Davis KJ, Yancey S, Crim C. Ecologic analysis of asthma-related events and dispensing of inhaled corticosteroid- and salmeterol-containing products. Ann Allergy Asthma Immunol 2008; 100: 558-565.
21. Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992; 21: 737-744.
22. Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J, Sutherland DC. A case-control study of deaths from asthma. Thorax 1986; 41: 833-839.
23. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev 2005; 4: CD005535.
24. Greenstone IR, Ni Chroinin MN, Masse V, et al. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; 4: CD005533.
25. Salpeter SR, Buckley NS, Orniston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904-912.
26. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med 2005; 353: 2637-2639.